News and Trends 15 Jan 2021 GSK Acne Deal Heralds Growing Interest in Skin Microbiome …of conditions such as metabolic diseases and even hangovers. The skin, the largest organ of the body, has an expansive microbiome, which opens new possibilities for precision bioengineering. In spite… January 15, 2021 - 4 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets …central nervous system (CNS), as well as metabolic diseases. Led by the former CSO of Ablynx, a biotech that was acquired by Sanofi for €3.9Bn earlier this year, Evox… September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Mar 2020 Phase III Fail for MedDay’s Multiple Sclerosis Treatment …protective sheath. After this setback, MedDay will now talk to regulators and evaluate the trial data. “I remain confident of the importance of the neurometabolic approach to neurodegenerative diseases with… March 11, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Mar 2025 These 7 biotechs are shaping the next generation of endometriosis care …Location: China Drug candidate: HMI-115 Technology: monoclonal antibody China-based Hope Medicine is building a pipeline focused on endocrine, cardiovascular and metabolic diseases as well as women’s health. The most advanced… March 25, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Link found between the Microbiome and “Genetic Obesity” …abdomen between internal organs. This belly fat carries a higher risk of metabolic diseases – such as type 2 diabetes. Figure 1. Consequences of visceral fat in the liver, muscles… October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close …of severe hypoglycemia, the biotech will have been keen to keep moving forward and ideally secure a strong position in the diabetes and metabolic diseases fields. Original news article: Alex… September 30, 2019 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Interview 6 May 2019 2019 Will Be a “Year of Realism” for Biotech Investments …mindset. “We believe that the hot areas always remain the same,” Hodits said. “What is still out there? What do people die of? They die of cancer, cardiac and metabolic… May 6, 2019 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2022 Evotec adds cell therapy manufacturing facility through Rigenerand takeover …develop innovative but cost-effective therapies for large patient numbers based on human cells to cure life-threatening diseases. Evotec’s current EVOcells project portfolio includes immuno-oncology, metabolic diseases and heart repair. Earlier… May 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 4 Jul 2024 The biggest private biotech investments in June 2024 …medicines for cardiometabolic diseases. Biotech investments by location in June 2024 When looking at the biggest private biotech investments by location, North America achieved the most funding rounds with 15… July 4, 2024 - 2 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback …with little to no treatment options,” said Uwe Andag, Head of Metabolic Diseases at the German drug development firm Evotec. Current CKD medications are generally limited to tackling the symptoms,… June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2022 New method of observing cell transport could inspire drug development …i.e. in the communication system of cells that allows them to coordinate their metabolic processes, development and organization. As a result, membrane proteins represent more than 60% of current drug… October 24, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2017 French Biotech gets a Boost in the NASH Race with a Successful IPO …types of the metabolic disorder mucopolysaccharidosis (MPS I, II and VI). On top of that, Inventiva has several preclinical candidates in oncology and is partnered with big players: AbbVie in… February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email